Skip to main content
Thu, Mar 19, 2026
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
HealthUnited States1 sourcesNeutral

Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) for technology...

CP
cision pr newswire
via Pr Newswire
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Comments

0 comments
Be respectful and constructive.
Loading comments...